Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma Clinical research trials and Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma. Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma clinical trial. Participants frequently obtain the most expert healthcare available for their Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.

Home > "V" Clinical Trials Conditions > Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma

Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma



Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma

For Condition: Stage 4 Melanoma,Recurrent Melanoma
Status: Recruiting
Sponsor(s): Hoag Memorial Hospital Presbyterian ,
Synopsis: RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have stage IV or recurrentmelanoma.
Details: OBJECTIVES: - Determine the safety of immunization with autologous in vitro-treated tumor cells and dendritic cells in combination with sargramostim (GM-CSF) in patients with stage IV or recurrent melanoma. - Determine the frequency of conversion of delayed tumor hypersensitivity tests in patients treated with this regimen. - Determine the progression-free and overall survival in patients treated with this regimen. - Determine the objective tumor response rate in patients with measurable melanoma treated with this regimen. OUTLINE: Patients are stratified according to presence of measurable disease at study initiation (yes vs no). Patients undergo tumor cell harvest. Patients with multiple persistent sites of metastatic disease after harvest may receive systemic therapy (biologic therapy and/or chemotherapy) during tumor cell line expansion over approximately 4 months. The tumor cell line is expanded, irradiated, and treated with interferon gamma. Patients undergo leukapheresis to collect peripheral blood mononuclear cells (PBMC) to obtain dendritic cells (DC). The PBMC are treated with sargramostim (GM-CSF) and interleukin-4 for 7 days to produce DC. The DC are then cultured with the treated tumor cells for 18 hours. Patients undergo delayed tumor hypersensitivity tests intradermally 1 week prior to vaccination and again at week 4. Patients receive vaccine therapy comprising autologous treated tumor cells and dendritic cells suspended in GM-CSF subcutaneously weekly for 3 weeks. Vaccine therapy continues monthly for an additional 5 months in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months for 1 year and then every 3 months for 4 years. PROJECTED ACCRUAL: A total of 30-80 patients will be accrued for this study.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 16 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed stage IV or recurrent melanoma - Metastatic disease confirmed by MRI or CT scan - Planned resection of tumor - No active CNS metastases - Radiographically confirmed lack of CNS disease progression - No requirement for pharmacologic doses of corticosteroids PATIENT CHARACTERISTICS: Age: - Over 16 Performance status: - ECOG 0-2 Life expectancy: - At least 4 months Hematopoietic: - Hematocrit greater than 25% - Platelet count greater than 100,000/mm^3 - No ongoing transfusion requirements - No active blood clotting or bleeding diathesis Hepatic: - Bilirubin no greater than 2.0 mg/dL - Albumin at least 3.0 g/dL Renal: - Creatinine no greater than 2.0 mg/dL Cardiovascular: - No underlying cardiac disease associated with known myocardial dysfunction - No unstable angina related to atherosclerotic cardiovascular disease Other: - No other malignancy within the past 5 years except for carcinoma in situ, basal cell carcinoma, or localized squamous cell skin cancer - No active, eminently life-threatening infection or medical condition - Adequate venous access - Not pregnant - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - Other prior putative vaccines allowed - Recovered from prior biologic therapy - No other concurrent biologic therapy except epoetin alfa for patients with hematocrit less than 36% Chemotherapy: - At least 3 weeks since prior chemotherapy and recovered - No concurrent chemotherapy Endocrine therapy: - See Disease Characteristics - No concurrent endocrine therapy Radiotherapy: - At least 3 weeks since prior radiotherapy (including whole brain radiotherapy) and recovered - No concurrent radiotherapy Surgery: - See Disease Characteristics - Recovered from prior surgery Other: - Concurrent bisphosphonates allowed for patients with lytic bone metastases - No concurrent digoxin or other medications designed to improve cardiac output - No other concurrent investigational therapy
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
RobertDillman,  Study Chair,  Hoag Memorial Hospital Presbyterian

Hoag Memorial Hospital Presbyterian *Recruiting*
Newport Beach,  California,  92658
United States
Recruiting Robert  Dillman 949-760-2091


Additional Information:
Study ID Numbers:  CDR0000068481;  HOAG-VACCINE-MEL,NCI-V01-1646
Study Start Date: 
Record last reviewed: December 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00012064

Other Stage 4 Melanoma Studies:
1. Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma

2. Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma

3. Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma

4. Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma

5. Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Related Studies:

Other Stage 4 Melanoma Clinical Trials
Other California Clinical Trials
Other Newport Beach Clinical Trials

Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma
Modify your Search

  Other Stage 4 Melanoma Clinical Trials
  Other California Clinical Trials
  Other Newport Beach Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103